ARA-290
Also known as: Cibinetide, ARA290
EPO-derived peptide (cibinetide) that activates the Innate Repair Receptor for tissue protection and nerve regeneration, without raising red-cell counts. Studied for neuropathic pain and inflammation.
Pharmacokinetics
- Half-life
- 20 min
- Time to peak
- 30 min
- Bioavailability
- 70%
- Onset
- 30 min
- Dosing interval
- 24h
Administration
- Primary routes
- SubQ
- Category
- Healing & Repair
Safety Flags
- Contraindicated in cancer history
Storage
- · Requires refrigeration (2–8°C)
- · Temperature sensitive — minimise room-temp exposure
Used in 1 outcome protocol
Simulate ARA-290
Pinned.life runs a 1-compartment Bateman pharmacokinetic simulation against 38 peptides in real time. Build a stack, see serum-level curves, get warned about peak overlaps and drug-peptide interactions.